A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta- analysis

Lung Cancer

Volumn 30, Issue 1, 2000, Pages 23-36

  Mascaux, C ^a   Paesmans, M ^a   Berghmans, T ^a   Branle, F ^a   Lafitte, J J ^b   Lemaitre F ^a   Meert, A P ^a   Vermylen, P ^a   Sculier, J P ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Cisplatin; Etoposide; Meta analysis; Small cell lung cancer; Systematic review

Indexed keywords

ALTRETAMINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; LOMUSTINE; METHOTREXATE; PROCARBAZINE; TENIPOSIDE; VINBLASTINE; VINCRISTINE; VINDESINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESEARCH; HUMAN; LUNG SMALL CELL CANCER; MEDICAL LITERATURE; META ANALYSIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033797356     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(00)00127-6     Document Type: Article

References (50)

1. Ihde D.C. Small cell lung cancer. State-of-the-art therapy 1994. Chest. 107:(6 (suppl.)):1995;243S-248S.
2. Chalmers T.C., Smith H. Jr, Blackburn B., Silverman B., Schoeder B., Reitman D., et al. A method for assessing the quality of a randomised clinical trial. Control. Clin. Trials. 2:1981;31-49.
3. Sculier J.P., Berghmans T., Castaigne C., Luce S., Sotiriou C., Vermylen P., Paesmans M. Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. Lung Cancer. 19:1998;141-151.
4. Luce S., Paesmans M., Berghmans T., Castaigne C., Sotiriou C., Vermylen P., Sculier J.P. Revue critique des études randomisées évaluant le rôle de la radiothérapie adjuvante à la chimiothérapie dans le traitement du cancer bronchique à petites cellules au stade limité Rev. Mal. Resp. 15:1998;633-641.
5. Sculier J.P., Berghmans T., Castaigne C., Lalami Y., Luce S., Sotiriou C., Vermylen P., Paesmans M. Best supportive care or chemotherapy for stage IV non small cell lung cancer. Van Houtte P., Klastersky J., Rocmans P. Progress and Perspectives in Lung Cancer. 1999;199-207 Springer, Berlin.
6. Marino P., Preatoni A., Cantoni A. Randomized trials of radiotherapy alone versus combinated chemotherapy and radiotherapy in stage IIIa and IIIb non small cell lung cancer. A meta-analysis. Cancer. 76:1995;593-601.
7. Marino P., Preatoni A., Cantoni A., Buccheri G. Single-agent chemotherapy versus combination chemotherapy in advanced non-small cell lung cancer: a quality and meta-analysis study. Lung Cancer. 13:(1):1995;1-12.
8. Parmar M.K.B., Toui V., Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat. Med. 17:(24):1998;2815-2834.
9. Yusuf S., Peto R., Lewis J. Beta-blocked during and after myocardial infarction: an overview of randomised trials. Prog. Cardiovasc. Dis. 27:1985;335-371.
10. Kanitz E., Kolaric K., Jassam J., Mechl Z., Pawlicki M., Ringwald G., Rolski J., Schoket Z.S., Vukas D., Kaplan E., Eckhardt S. Randomized phase II trial of high-dose 4′-épi-doxorubicin+cyclophosphamide versus high-dose 4′-épi-doxorubicin+cisplatin in previously untreated patients with extensive small cell lung cancer. Oncology. 49:1992;327-332.
11. Daniels J.R., Chak L.Y., Sikic B.I., Lockbaum P., Kohler M., Carter S.K., Reynolds R., Bohnen R., Gandara D., Yu J. Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs. J. Clin. Oncol. 2:1984;1192-1199.
12. Livingston R.B., Mira J.G., Chen T.T., Mcgavran M., Costanzi J.J., Samson M. Combined modality treatment of extensive small-cell lung cancer: a Southwest Oncology Group study. J. Clin. Oncol. 2:1984;585-590.
13. Lowenbraun S, Bartolucci AL, Shalley RV, Lynn M, Krauss S, Durantt JR and the Southestern Cancer Study Group. Combination chemotherapy in small-cell lung carcinoma. A randomized study of two intensive regimens. Cancer 1984;54:2344-2350.
14. Hirsch F., Hansen H., Hansen M., Osterlind K., Vindelov L., Dombernowsky P., Sorensson S. The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small-cell lung cancer: a randomized trial of 288 consecutive patients. J. Clin. Oncol. 5:1987;585-591.
15. Messeih A.A., Schweitzer J.M., Lipton A., Harvey H.A., Simmonds M.A., Styker J.A., Ricci J.A., Hoffman S.L., Gottleib R.J., Dixon R.H., Shope E.S., Meloy J.M., Walker B.K., Gordon R.A., Heckard R., White D.S. Addition of etoposide to cyclophosphamide, doxorubicin and vincristine for remission induction and survival in patients with small-cell lung cancer. Cancer Treat. Rep. 71:1987;61-66.
16. Jackson Jr D.V., Zekan P.J., Caldwell R.D., Slatkoff M.L., Harding R.W., Case L.D., Hopkins J.O., Hyman B.M., Richards I.I.F., White D.R., Cooper M.R., Stuart J.L., Capizzi R.L., Spurr C.L. VP-16-213 in combinaition chemotherapy with chest irradiation for small-cell lung cancer: a randomized trial of the Piedmont Oncology Association. J. Clin Oncol. 2:1984;1343-1351.
17. Jackson Jr D.V., Case L.D. Small cell Lung cancer: a 10-year perspective. Semin. Oncol. 12:1986;63-74.
18. Jackson Jr D.V., Case L.D., Zekan P.J., Powell B.L., Caldwell R.D., Bearden J.D., Nelson E.C., Muss H.B., Cooper M.R., Richards I.I.F., White D.R., Cruz J.M., Caponera M.E., Furr C.S., Spurr C.L., Capizzi R.L. Improvement of long-term survival in extensive small-cell lung cancer. J. Clin. Oncol. 6:1988;1161-1169.
19. Everson L., Jett J., O'Fallon J., Krook J., Dalton R., Mailliard J., Tschetter L., Cullinan S., Gerstner J., Morton R., Laurie J. Alternating chemotherapy with or without VP-16 in extensive-stage small-cell lung cancer. Am. J. Clin. Oncol. 12:(4):1989;339-344.
20. Hong W., Nicaise C., Lawson R., Maroun J., Comis R., Speer J., Luedke D., Hurtubise M., Lanzotti V., Goodlow J., Rozencweig M. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the British Lung Cancer Study Group. J. Clin. Oncol. 7:1989;450-456.
21. McIllmurray M., Ribby R., Taylor B., Ormerod L., Edge J., Wolstenholme R., Willey R., O'Reilly J., Horsfield N., Johnson C., Mustchin C., Briscoe D. Etoposide compared with the combination of vincristine, doxorubicin, and cyclophosphamide in the treatment of small cell lung cancer. Thorax. 44:1989;218-219.
22. Ettinger D.S., Finkelstein D.M., Abeloff M.D., Ruckdeschel J.C., Aisner S.C., Eggleston J.C. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive stage small cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 8:1990;230-240.
23. Jett J.R., Everson L., Therneau T.M., Krook J.E., Dalton R.J., Marschke R.F. Jr, Veeder M.H., Brunk S.F., Maillard J.A., Twito D.I., Earle J.D., Anderson R.T. Treatment of limited stage small-cell lung cancer. Two-drug with cyclophosphamide, doxorubicin and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group. J. Clin. Oncol. 8:1990;33-39.
24. Nikkanen V, Liippo K, Ojala A, Jakobsson M, Järvinen M, Paloheimo S, Norman E. Vincristine, doxorubicin and cyclophosphamide with and without etoposide in limited small cell lung cancer. Acta Oncol 1990;29:421-424.
25. Jones A., Holborn J., Ashley S., Smith I. Effective new low toxicity chemotherapy with carboplatin, vinblastine and methotrexate for small cell lung cancer: a randomised trial against doxorubicin, cyclophosphamide and etoposide. Eur. J. Cancer. 27:1991;866-870.
26. Nou E., Lamberg K., Brodin O. Etoposide versus methotrexate in small cell bronchial carcinoma: a randomized study of two types of four-drug chemotherpay regimens. Acta Oncol. 31:1992;853-860.
27. Postmus P, Scagliotti G, Groen H, Gozzelino F, Burghouts J, Curran D, Sahmoud T, Kirkpatrick A, Giaccone G, Splinter T. Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer as: an EORTC phase III trial. Eur J Cancer 1996;32:1498-1503.
28. Erkisi M., Unsal M., Tunali C., Burgut R., Doran F. A randomized study comparing cyclophosphamide, doxorubicin, vincristine (CAV) with cyclophosphamide, etoposide, vincristine, methotrexate (CEVM) in patients with small cell lung cancer. J. Chemother. 5:1993;56-59.
29. Abratt R., Salton D., Malan J., Willcox P. A prospective randomised study in limited disease small cell carcinoma - doxorubicin and vincristine plus either cyclophosphamide or etoposide. Eur. J. Cancer. 31:1995;1637-1639.
30. Evans W.K., Feld R., Murray N., Willan A., Coy P., Osoba D., Shepherd F.A., Clark D.A., Levitt M., Macdonald A., Wilson K., Shelley W., Pater J. Superiority of alternating non-cross resistant chemotherapy in extensive small-cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Ann. Int. Med. 107:1987;451-458.
31. Havemann K., Wolf M., Holle R., Gropp C., Drings P., Manke H.G., Hans K., Schroeder M., Heim M., Victor N., Georgii A., Thomas C., Pflüger K.H., Bepler G. Alternating versus sequential chemotherapy in small-cell lung cancer. A randomized german multicenter trial. Cancer. 59:1987;1072-1082.
32. Fukuoka M., Furuse K., Saijo N., Nishiwaki Y., Ikegami H., Tamura T., Shimoyama M., Suemasu K. Randomized trial of cyclophosphamide, doxorubicin and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer. J. Natl. Cancer Inst. 83:1991;855-861.
33. Wampler GL, Heim WJ, Ellison NM, Ahlgren JD, Fryer JG for the Mid-Atlantic Oncology Program. Comparison of cyclophosphamide, doxorubicin and vincristine with an alternating regimen of methotrexate, etoposide and cisplatin/cyclophosphamide, doxorubicin and vincristine in the treatment of extensive-disease small cell lung carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1991;9:1438-1445.
34. Monnet I, Chariot P, Qouix E, Ruffie P, Voisin S, Le Chevalier T, Saltiel J, De Cremoux H and Association pour le traitement des tumeurs intra-thoraciques (ATTIT). Extensive small-cell lung cancer. A randomized comparison of two chemotherapy programs with early crossover in instances of failure. Ann Oncol 1992;3:813-817.
35. Roth B.J., Johnson D.H., Einhorn L.H., Schacter L.P., Cherng N.C., Cohen H.J., Crawford J., Randolph J.A., Goodlow J.L., Broun G.O., Omura G.A., Greco F.A. Randomized study of cyclophosphamide, doxorubicin and vincristine versus etoposide and cisplatin versus alternation of the two regimens in extensive small cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J. Clin. Oncol. 10:1992;282-291.
36. Einhorn L.H., Crawford J., Birch R., Omura G., Johnson D.H., Greco F.A. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin and vincristine in limited small-cell lung cancer. J. Clin. Oncol. 6:1988;451-456.
37. Johnson D.H., Bass D., Einhorn L.H., Crawford J., Perez C.A., Bartolucci A., Omura G.A., Greco F.A. Combination chemotherapy with or without thoracic radiotherapy in limited stage small-cell lung cancer: a randomised trial of the Southeastern cancer Study Group. J. Clin. Oncol. 11:1993;1223-1229.
38. Farris A., Bisail M., Sarobba M., Sanna G., Scotto T., Valzelli S., Intini C. Cisplatin-VP16 alternating with cyclophosphamide-epirubicin versus cyclophosphamide-epirubicin-vincristine in small cell lung cancer. J. Chemother. 5:1993;344-347.
39. Veronesi A., Cartei G., Crivellari D., Magri M., Della Valentina M., Foladore S., Trovo M., Nascimben O., Sibau A., Talamini R., Monfardini S. Cisplatin and etoposide versus cyclophosphamide, epirubicin and vincristine in small cell lung cancer: a randomised study. Eur. J. Cancer. 30:1994;1474-1478.
40. Wolf M., Havemann K., Holle R., Gropp C., Drings P., Hans K., Schroeder M., Heim M., Dommes M., Mende S., Thiel H., Hruska D., Victor N., Georgii A., Braun C. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter german randomized trial. J. Clin. Oncol. 5:1987;1880-1889.
41. Goodman G.E., Crowley J.J., Blasko J.C., Livingston R.B., Beck T.M., Demattia M.D., Bukowski R.M. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group study. J. Clin. Oncol. 8:1990;39-47.
42. Sculier JP, Klastersky J, Libert P, Ravez P, Thiriaux J, Lecomte J, Bureau G, Vandermoten G, Dabouis G, Michel J, Schmerber J; Sergysels R, Becquart D, Mommen P, Paesmans M for the EORTC Lung Cancer Working Party. A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small-cell lung cancer. Ann Oncol 1990;1:128-133.
43. Smith A.P., Anderson G., Chappell G., Bowen D.R. Does the substitution of cisplatin in a standard four drug regimen improve survival in small cell carcinoma of the lung? A comparison of two chemotherapy regimens. Thorax. 46:1991;172-174.
44. Sculier J.P., Paesmans M., Bureau G., Dabouis G., Libert P., Vandermoten G., Van Cutsem O., Berchier M.C., Ries F., Michel J., Sergysels R., Mommen P., Klastersky J. Multiple drug weekly chemotherapy versus standard combination regimen in small cell lung cancer: a phase III randomised study conducted by the European Lung Cancer Working Party. J. Clin. Oncol. 11:1993;1858-1865.
45. Joss R.A., Albert P., Bleher E.A., Ludwig C., Siegenthaler P., Martinelli G., Sauter C., Schatzmann E., Senn H.J. Combined-modality treatment of small-cell lung cancer: randomized comparison of three induction chemotherapies followed by maintenance chemotherapy with or without radiotherapy to the chest. Ann. Oncol. 5:1994;921-928.
46. Kosmidis P.A., Samantas E., Fountzilas G., Pavlidis N., Apostolopoulou F., Skarlos D.V. Cisplatin/etoposide versus Carboplatin/etoposide chemotherapy and irrdadiation in small cell lung cancer: a randomized phase III study. Semin. Oncol. 21:(suppl 6):1994;23-30.
47. Skarlos DV, Samantas E, Kosmidis PA, Fountzilas G, Angelidopu M, Palamidas P, Mylonakis N, Provata A, Papadakis E, Klouvas G, Theocharis D, Panousaki E, Boleti E, Sphakianoudis G, Pvalidis N. Randomized comparison of etoposide-cisplatin vs etoposide-carboplatin and irradiation in small cell lung cancer. Ann Oncol 1994;5:601-607.
48. Joss RA, Bacchi M, Hurny C, Bernhard J, Cerny T, Martinelli G, Leyvraz S, Senn Hj, Stahel R, Siegenthaler P, Ludwig C, Alberto P for the Swiss Group for Clinical Cancer Research (SAKK). Early versus late alternating chemotherapy in small-cell lung cancer. Ann Oncol 1995;6:157-166.
49. Souhami R.L., Spiro S.G., Rudd R.M., Ruiz De Elvira M.C., James L.E., Gower N.H., Lamont A., Harper P.G. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J. Natl. Cancer Inst. 89:1997;577-580.
50. Stewart L.A., Parmar M.K.B. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet. 341:1993;418-422.